Who to call at BioAtla, Inc., and when
Fundz watches for the moments BioAtla, Inc. starts buying, and tells you who to reach.
- An alert the day BioAtla, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BioAtla, Inc., from your own LinkedIn network
BioAtla, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
The seat is still open. No replacement has been named 30 days after this filing.
See every company with multiple executive changes →AI Executive Summary
AI-powered analysis of 8-K filing content
Dr. Eric Sievers resigned as Chief Medical Officer of BioAtla on September 25, 2026, to pursue outside interests, but will continue as a consultant through June 30, 2027. His compensation includes a one-time $159,000 payment contingent on the company achieving specific capital raising milestones by December 31, 2026.
Key Takeaways
Chief Medical Officer departure represents a leadership transition that may impact clinical strategy and decision-making
Contingent $159,000 payment tied to capital raising milestones suggests the company is actively pursuing fundraising by year-end 2026
2 more takeaways
Related Filings (1)
1 more filing from BioAtla, Inc. in the last 90 days
Filing Overview
What This Means
BioAtla, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.